SlideShare uma empresa Scribd logo
1 de 28
 
Treatment may be worse than the disease
During the 1990’s, the deaths of two healthy volunteers in the US made their way to the highest political levels  and forced a review of protection of human subjects.   Ellen Roche 24 year old Healthy Volunteer Asthma study Jesse Gelsing er 18  year old   Healthy Volunteer Genetic Study
In March of 1994, the U.S. Office of Research Integrity announced that Dr. Roger Poisson from Montreal admitted having falsified data (99 cases) in a breast cancer clinical trial sponsored by the U.S. National Cancer Institute (NCI). This well-intended falsification compromised the contribution of hundreds of women enrolled in the protocol as all data from the 389 patients enrolled by Dr Poisson were removed from the analysis. Dr. Roger Poisson
 
We need sound science, ethics and safety in clinical trials to sustain the trust of government, public and, especially, the research subjects.
Limitations of addressing Patient Safety in clinical trials  ,[object Object],[object Object],[object Object],[object Object]
Thus, in order to have complete assessment of the drug in real life setting, safety reporting in post-authorisation era or pharmacovigilance is equally important.
Legal Basis of Volume 9A ,[object Object],[object Object]
Structure of Volume 9A ,[object Object],[object Object],[object Object],[object Object]
Part I - Roles & Responsibilities of the MAH ,[object Object],[object Object],[object Object]
EU Qualified Person for Pharmacovigilance ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],EU Qualified Person for Pharmacovigilance
Responsibilities of MAH ,[object Object],[object Object],[object Object],[object Object],[object Object],I have the drug license
Detailed Description of the PV System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmacovigilance Inspections ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Risk Management System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Safety Reporting in Post-authorisation period ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Safety Reporting in Post-authorisation period ,[object Object],[object Object],[object Object],[object Object]
Post-Authorisation Safety Studies   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Risk-Benefit Assessment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Part II – Undertaking of PV activity by  Competent Authorities and the Agency ,[object Object],[object Object],[object Object],[object Object]
Rapid Alert and Non-Urgent Information System in Pharmacovigilance ,[object Object],[object Object],[object Object]
Part III – Electronic exchange of PV information in the EU ,[object Object],[object Object],[object Object],[object Object]
Part IV – Direct Healthcare Professional Communications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PV Regulatory Environment in the US and Japan ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Final thoughts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Study Protocol : PRC/CRD/33/08  Capecitabine 500 mg tablets
 

Mais conteúdo relacionado

Mais procurados

Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australianandiniwarier93
 
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxVOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxAartiVats5
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safetyAzierta
 
Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification programshweta more
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)VivekWagh13
 
Pharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European UnionPharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European UnionBindu Kshtriya
 
schedule y
schedule yschedule y
schedule yRohit K.
 
Who is the EU QPPV and what do they do
Who is the EU QPPV and what do they doWho is the EU QPPV and what do they do
Who is the EU QPPV and what do they doFiorenza Gaudenzi
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSKatalyst HLS
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japanAadityaThole
 

Mais procurados (20)

CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australia
 
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxVOLUME 9A ppt.pptx
VOLUME 9A ppt.pptx
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
Ich e6(r1)
Ich e6(r1)Ich e6(r1)
Ich e6(r1)
 
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
 
Pharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European UnionPharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European Union
 
schedule y
schedule yschedule y
schedule y
 
Who is the EU QPPV and what do they do
Who is the EU QPPV and what do they doWho is the EU QPPV and what do they do
Who is the EU QPPV and what do they do
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLS
 
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Fda guidance for pharmaceutical post marketing reporting   professor pirouziFda guidance for pharmaceutical post marketing reporting   professor pirouzi
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
 
ANDA
ANDAANDA
ANDA
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japan
 
New EU PV regulations
New EU PV regulationsNew EU PV regulations
New EU PV regulations
 
GHTF
GHTFGHTF
GHTF
 

Destaque

Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance pptPrasad Bhat
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full informationRavindra Kumar
 
Top 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answersTop 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answerstonychoper3006
 
Causality assessment scales
Causality assessment scalesCausality assessment scales
Causality assessment scalesDr Renju Ravi
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilanceNahla Amin
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Until ROI
 
Pharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspectivePharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspectiveTGA Australia
 
Acceleration Brochure Japanese
Acceleration Brochure JapaneseAcceleration Brochure Japanese
Acceleration Brochure Japaneserobbpoe
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice Inclarityeye
 
ICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guidelineICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guidelinebibilicavesela
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshopinemet
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlineschandroo80
 
FDA News Presentation
FDA News PresentationFDA News Presentation
FDA News PresentationBoris Videlov
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilanceBhaswat Chakraborty
 

Destaque (20)

Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance ppt
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Top 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answersTop 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answers
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Causality assessment scales
Causality assessment scalesCausality assessment scales
Causality assessment scales
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilance
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
 
MAGI Presentation
MAGI PresentationMAGI Presentation
MAGI Presentation
 
Pharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspectivePharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspective
 
Acceleration Brochure Japanese
Acceleration Brochure JapaneseAcceleration Brochure Japanese
Acceleration Brochure Japanese
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice In
 
ICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guidelineICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guideline
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshop
 
Spontaneous reporting
Spontaneous reporting Spontaneous reporting
Spontaneous reporting
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlines
 
FDA News Presentation
FDA News PresentationFDA News Presentation
FDA News Presentation
 
PSUR Requirements
PSUR RequirementsPSUR Requirements
PSUR Requirements
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilance
 

Semelhante a Volume 9 A Guidelines On Pharmacovigilance[1]

Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURAzierta
 
conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products  conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products Bindu Kshtriya
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulationsUntil ROI
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuAngelinabarfield
 
3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptxKrishnapriyaVH1
 
Common arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilanceCommon arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilanceNahla Amin
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
Regulatory requirements of eu & mhra trilok
Regulatory requirements of eu & mhra  trilokRegulatory requirements of eu & mhra  trilok
Regulatory requirements of eu & mhra trilokTrilok Shahare
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONgarimasaini33
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safetyLanre Suleiman
 
Dossier on Drug Safety.
Dossier on Drug Safety.Dossier on Drug Safety.
Dossier on Drug Safety.Lanre Suleiman
 
Regulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptxRegulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptxAnkushAwatale
 
Regulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGARegulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGAHimal Barakoti
 
European Clinical Trial Safety Focus
European  Clinical Trial Safety FocusEuropean  Clinical Trial Safety Focus
European Clinical Trial Safety FocusVaska Toné
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxBharatRRDesai
 
POST MARKETING SURVILLANCE
 POST  MARKETING SURVILLANCE POST  MARKETING SURVILLANCE
POST MARKETING SURVILLANCE08908151381
 
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015KCR
 

Semelhante a Volume 9 A Guidelines On Pharmacovigilance[1] (20)

Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
 
conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products  conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And Eu
 
3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx
 
Common arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilanceCommon arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilance
 
Safety report filing
Safety report filingSafety report filing
Safety report filing
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Regulatory requirements of eu & mhra trilok
Regulatory requirements of eu & mhra  trilokRegulatory requirements of eu & mhra  trilok
Regulatory requirements of eu & mhra trilok
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNION
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safety
 
Dossier on Drug Safety.
Dossier on Drug Safety.Dossier on Drug Safety.
Dossier on Drug Safety.
 
Regulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptxRegulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptx
 
Regulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGARegulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGA
 
European Clinical Trial Safety Focus
European  Clinical Trial Safety FocusEuropean  Clinical Trial Safety Focus
European Clinical Trial Safety Focus
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
 
pharmacovigilance study
pharmacovigilance studypharmacovigilance study
pharmacovigilance study
 
POST MARKETING SURVILLANCE
 POST  MARKETING SURVILLANCE POST  MARKETING SURVILLANCE
POST MARKETING SURVILLANCE
 
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
 

Volume 9 A Guidelines On Pharmacovigilance[1]

  • 1.  
  • 2. Treatment may be worse than the disease
  • 3. During the 1990’s, the deaths of two healthy volunteers in the US made their way to the highest political levels and forced a review of protection of human subjects. Ellen Roche 24 year old Healthy Volunteer Asthma study Jesse Gelsing er 18 year old Healthy Volunteer Genetic Study
  • 4. In March of 1994, the U.S. Office of Research Integrity announced that Dr. Roger Poisson from Montreal admitted having falsified data (99 cases) in a breast cancer clinical trial sponsored by the U.S. National Cancer Institute (NCI). This well-intended falsification compromised the contribution of hundreds of women enrolled in the protocol as all data from the 389 patients enrolled by Dr Poisson were removed from the analysis. Dr. Roger Poisson
  • 5.  
  • 6. We need sound science, ethics and safety in clinical trials to sustain the trust of government, public and, especially, the research subjects.
  • 7.
  • 8. Thus, in order to have complete assessment of the drug in real life setting, safety reporting in post-authorisation era or pharmacovigilance is equally important.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.  

Notas do Editor

  1. Ensure u hv a DDPVS ready, correct resources, processes are clearly documented, QC is built in, agreements in place
  2. Regulation EC) No 726/2004 and Directive 2001/83/EC
  3. Unknown = Unexpected US – Safety reporting requirements are specified in Title 21